Tarsus Pharmaceuticals, Inc. TARS Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s business segments — net loss?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — net loss of -$6.97M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — net loss changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — net loss increased by 72.3% year-over-year, from -$25.12M to -$6.97M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — net loss has grown at a 2.3% compound annual growth rate (CAGR), from -$62.09M to -$66.42M.
- What does business segments — net loss mean?
- Represents the bottom-line financial result of the business segment after accounting for all revenues, operating expenses, and non-operating items. A persistent net loss is common in growth-stage biopharmaceutical companies investing heavily in commercialization and R&D.